Navigation Links
StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
Date:2/28/2013

LONDON, February 28, 2013 /PRNewswire/ --

Markets responded well to Fed chief Ben Bernanke's remarks about the stimulus policy. On the other hand, there are some worries about the ongoing Sequestration debate as well. However, broader indices remained in the green and The Dow Jones closed 1.26% higher at 14,075.37, the S&P 500 closed 1.27% higher at 1,515.99, and the NASDAQ closed 1.04% higher at 3,162.26. Our research team took a look at major drug makers stocks including companies like Eli Lilly & Co. (NYSE: LLY), Bristol Myers Squibb Co. (NYSE: BMY), Astex Pharmaceuticals Inc. (NASDAQ: ASTX) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). StockCall has issued technical analysis and charting reports on LLY, BMY, ASTX and RPTP. Download these free reports now at http://www.stockcall.com/todaysopinions

Eli Lilly & Co. is currently in a bullish mode as the stock created a new 52-week high price in its latest trading session. The stock closed the session at $54.80, up 0.68 percent. Eli Lilly traded in the range of $54.26 and $54.99 during the session. Its first support level is at $53.83 and upon breaching this level, the stock may go down to $52.46 level. On the upside, Eli Lilly & Co.'s stock may touch $57.44 level. The stock has traded in the range of $38.56 and $54.99 in the past 52 weeks and it grew by 40 percent during the same time period. On a Year-to-Date basis, the stock is up 11.11 percent. Download the free research on LLY today by registering at http://www.StockCall.com/LLY022813.pdf

Bristol Myers Squibb Co.'s shares also touched a new 52-week high in its latest trading session, ending the day 1.95 percent higher at $37.10. The stock fell to an intra-day low of $36.31, while its intra-day high stood at $37.22. With the upward movement, the stock grew more than 13 percent this year, compared to a gain of 6.3 percent for the S&P 500. The stock has strong support at around $37.03, as it shows a bullish trend. The stock is trading below than its 20-day and 50-day moving averages. Sign up and have access to our free report on BMY at http://www.StockCall.com/BMY022813.pdf

Astex Pharmaceuticals traded in the range of $3.08 and $3.24 in its latest trading session and ended it at $3.19, up 1.92 percent. The stock's 52 weeks range stands at $1.57 and $3.55. Astex Pharma. is up 62.76 percent in the past 12 months, while it gained 9 percent so far this year. The stock is in a bullish mode and may find its first support level at $3.17. It is trading below its 20-day moving average of $3.29 but above its 50-day average price of $3.14. Sign up and read the complimentary report on ASTX at http://www.StockCall.com/ASTX022813.pdf

Shares of Raptor Pharma ended their previous trading session marginally lower at $4.98, down 0.40 percent. The stock lost more than 14 percent this year, in contrast to the broad market. The stock has slipped from $5.03 resistance level. It has support at around $4.87 at the moment. With its downward movement, Raptor is trading below its 20-day moving average price. The stock may touch $5.08 level in the coming trading sessions. The free report on RPTP can be downloaded by signing up now at http://www.StockCall.com/RPTP022813.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. StockCall Research on Boston Scientific and Medtronic: Focus on Paroxysmal Atrial Fibrillation
2. Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
3. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
4. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
5. Omnyx Share Their Insight on Agile Software Development for Medical Devices
6. Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends
7. GlaxoSmithKline Share Their Insight on Understanding DDI With a View to Better Prediction and Control
8. Pro-Dex Provides Insight Into Fiscal 2013 Operating Plan And Preliminary Results For Fiscal 2012
9. Indegene Introduces TrialPedia 2.0 with Advantage Insights, Making It the Most Comprehensive Clinical Trial Analytics and Decision Support Platform for the Pharma Industry
10. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
11. New Survey Reveals How Patients Choose Their Pharmacy; AccentHealth Garners Consumer Insights from the Waiting Room
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
Breaking Medicine News(10 mins):